Dr. Hector Chapa explores barriers in community health with Dr. Robert Carpenter, Director of Wellness at Texas A&M University College of Medicine, and Dr. Toni Keaton, Assistant Clinical Professor of Internal Medicine at Texas A&M College of Medicine.
Concerns in the Community: Obstacles to Accessing the COVID-19 Vaccine
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Details
Presenters
Overview
Dr. Hector Chapa explores barriers in community health with Dr. Robert Carpenter, Director of Wellness at Texas A&M University College of Medicine, and Dr. Toni Keaton, Assistant Clinical Professor of Internal Medicine at Texas A&M College of Medicine.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
0.50 credits
<p>IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base</p>
CME/CE
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
0.50 credits
<p>IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue</p>
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
1.00 credits
<p>Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
CME/CE
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
<p>FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure</p>
MinuteCE®
First-line Chemotherapy Options in Metastatic PDAC
0.25 credits
<p>First-line Chemotherapy Options in Metastatic PDAC</p>
MinuteCE®
Second-line Chemotherapy Options in Metastatic PDAC
0.25 credits
<p>Second-line Chemotherapy Options in Metastatic PDAC</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?